Browse by author
Lookup NU author(s): Emeritus Professor David Bates
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Natalizumab is a new treatment option for patients with active relapsing-remitting multiple sclerosis. In phase III studies, natalizumab was highly effective and well tolerated; however, three cases of progressive multifocal leucoencephalopathy (PML) were identified (estimated incidence of one per 1000; 95% CI 0.2-2.8; mean treatment period 17.9 months). In this Review we summarise the current information on PML, the three confirmed cases of PML, and the results of an extensive safety assessment of all patients treated with natalizumab. On the basis of these reviews, we make recommendations for appropriate selection of candidates for natalizumab and pretreatment assessments. In addition, a three-step diagnostic and management algorithm was developed to monitor natalizumab-treated patients with multiple sclerosis for PML and other opportunistic infections. The algorithm includes strategies for clinical, MRI, and laboratory assessments. Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed.
Author(s): Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Houser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major E, Clifford DB
Publication type: Review
Publication status: Published
Journal: Lancet Neurology
Year: 2007
Volume: 6
Issue: 5
Pages: 431-441
ISSN (print): 1474-4422
ISSN (electronic): 1474-4465
URL: http://dx.doi.org/10.1016/S1474-4422(07)70078-9
DOI: 10.1016/S1474-4422(07)70078-9
